NASDAQ:MRSN - Mersana Therapeutics Stock Price, Forecast & News

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

Mersana Therapeutics Inc (NASDAQ:MRSN) announced its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.02. The company earned $0.84 million during the quarter, compared to analysts' expectations of $0.50 million. Mersana Therapeutics had a negative return on equity of 41.14% and a negative net margin of 79.49%. View Mersana Therapeutics' Earnings History.

Mersana Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, February 28th 2020. View Earnings Estimates for Mersana Therapeutics.

Mersana Therapeutics will be holding an earnings conference call on Friday, February 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

4 brokerages have issued 1-year target prices for Mersana Therapeutics' shares. Their forecasts range from $12.00 to $12.00. On average, they anticipate Mersana Therapeutics' share price to reach $12.00 in the next year. This suggests a possible upside of 33.0% from the stock's current price. View Analyst Price Targets for Mersana Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mersana Therapeutics.

Media headlines about MRSN stock have been trending neutral recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Mersana Therapeutics earned a coverage optimism score of 0.4 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Mersana Therapeutics.

Mersana Therapeutics saw a increase in short interest in January. As of January 31st, there was short interest totalling 1,800,000 shares, an increase of 68.2% from the January 15th total of 1,070,000 shares. Based on an average trading volume of 385,200 shares, the short-interest ratio is presently 4.7 days. Approximately 5.6% of the shares of the company are short sold. View Mersana Therapeutics' Current Options Chain.

Some companies that are related to Mersana Therapeutics include Aimmune Therapeutics (AIMT), Alder Biopharmaceuticals (ALDR), TG Therapeutics (TGTX), Corcept Therapeutics (CORT), Constellation Pharmaceuticals (CNST), Innoviva (INVA), Nabriva Therapeutics (NBRV), Theravance Biopharma (TBPH), ZEALAND PHARMA/S (ZEAL), Dicerna Pharmaceuticals (DRNA), Endo International (ENDP), Madrigal Pharmaceuticals (MDGL), Intra-Cellular Therapies (ITCI), Zogenix (ZGNX) and Y-mAbs Therapeutics (YMAB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include Agile Therapeutics (AGRX), Nabriva Therapeutics (NBRV), VBI Vaccines (VBIV), vTv Therapeutics (VTVT), Eyepoint Pharmaceuticals (EYPT), Fortress Biotech (FBIO), ImmunoGen (IMGN), Marinus Pharmaceuticals (MRNS), Aduro BioTech (ADRO) and Crispr Therapeutics (CRSP).

(MRSN) raised $75 million in an IPO on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Mersana Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include BVF Inc. IL (2.47%), Renaissance Technologies LLC (1.50%), State Street Corp (1.30%), Geode Capital Management LLC (1.11%), Oxford Asset Management LLP (0.42%) and Bank of New York Mellon Corp (0.41%). Company insiders that own Mersana Therapeutics stock include Enterprise Associates 14 New and Timothy B Lowinger. View Institutional Ownership Trends for Mersana Therapeutics.

MRSN stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Point72 Asset Management L.P., Panagora Asset Management Inc., Renaissance Technologies LLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for Mersana Therapeutics.

MRSN stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Geode Capital Management LLC, Assenagon Asset Management S.A., Acadian Asset Management LLC, California Public Employees Retirement System, Oxford Asset Management LLP, Quantitative Systematic Strategies LLC and State Street Corp. View Insider Buying and Selling for Mersana Therapeutics.

Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MRSN stock can currently be purchased for approximately $9.02.

Mersana Therapeutics has a market capitalization of $431.91 million and generates $10.59 million in revenue each year. The company earns $-64,260,000.00 in net income (profit) each year or ($2.79) on an earnings per share basis. Mersana Therapeutics employs 86 workers across the globe.View Additional Information About Mersana Therapeutics.

The official website for Mersana Therapeutics is http://www.mersana.com/.

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]